How did Blueprint Medicines' revenue and expenses trend in Q4 2024?

In Q4 2024, Blueprint Medicines Corporation (BPMC) experienced a significant decline in net income, with a reported loss of $67.09 million. However, the company's total revenue remained stable at $508.82 million. The research and development (R&D) expenses were $341.43 million. |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |BPMC|BPMC.O|Blueprint Medicines|2024 Q1|168.79901204075333|8.9136E7|185| |BPMC|BPMC.O|Blueprint Medicines|2024 Q2|62.35193120119283|-4.9994E7|185| |BPMC|BPMC.O|Blueprint Medicines|2024 Q3|57.912843179047655|-5.6276E7|185| |BPMC|BPMC.O|Blueprint Medicines|2024 Q4|54.96051065671319|-4.9956E7|185| |code|Ticker|Name|Date|Total Revenue (FY)|R&D Expenses (FY)|Net Income (FY)|market_code| |---|---|---|---|---|---|---|---| |BPMC|BPMC.O|Blueprint Medicines|2024|5.08824E8|3.41433E8|-6.7089E7|185|